FINWIRES · TerminalLIVE
FINWIRES
Eli Lilly and Company

Eli Lilly and Company

$LLY
NYSEHealthcare

147 stories mentioning Eli Lilly and CompanyUpdated 7h ago

Eli Lilly trades amid a proposed permanent CMS Medicare drug price negotiation framework; an executive sold $2.88 million in shares per an SEC filing.

Wire

Market Chatter: Eli Lilly Plans to Sell About $8 Billion of Bonds to Fund Acquisitions

Eli Lilly (LLY) is looking to raise about $8 billion from an investment-grade bond sale to fund an acquisition spree, Bloomberg reported Wednesday, citing people with direct knowledge of the matter.The company is offering notes in as many as eight tranches, with maturities ranging from two to 40 years, according to the report.Proceeds will be used for general corporate purposes and potentially fund all or part of the upfront cash consideration and related expenses linked to the Centessa Pharmaceuticals (CNTA) and Kelonia Therapeutics acquisitions, Bloomberg said.Eli Lilly did not immediately respond to a request for comment by.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $991.81, Change: $+2.94, Percent Change: +0.30%

$CNTA$LLY
Wire

Eli Lilly to Invest Additional $4.5 Billion in Indiana Manufacturing Sites

Eli Lilly (LLY) said Wednesday it will invest an additional $4.5 billion in two of its facilities in Lebanon, Indiana, bringing its total capital expansion commitments in the state to more than $21 billion since 2020.The additional investment will fund new process designs and technologies at Lilly Lebanon Advanced Therapies, a dedicated genetic medicine plant opening Wednesday, and Lilly Lebanon API, an active pharmaceutical ingredient facility expected to open in 2027, the company said.The Lebanon Advanced Therapies site is designed to handle operations ranging from clinical research to commercial production of therapies targeting diseases at the genetic level, Lilly said.The Lebanon campus will also include the planned Lilly Medicine Foundry facility, the company said.Price: $987.86, Change: $-0.61, Percent Change: -0.06%

$LLY
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Monday afternoon, with the NYSE Health Care Index decreasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.4%.The iShares Biotechnology ETF (IBB) rose 1.6%.In corporate news, Sanofi (SNY) said Monday it will invest 294 million Canadian dollars ($216 million) to expand its global AI Centre of Excellence in Toronto in a bid to accelerate the development and delivery of medicines. Its shares were down past 5%.Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico. Amgen shares were down 2.1%.Eli Lilly (LLY) shares added 0.7% after Barclays lifted the company's price target to $1,400 from $1,350, while keeping its overweight rating.Vanda Pharmaceuticals (VNDA) shares jumped past 7% after it said Monday its motion sickness drug Nereus is now commercially available in the US.

$AMGN$LLY$SNY$VNDA
Sectors

Sector Update: Health Care Stocks Softer in Afternoon Trading

Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.3%.The iShares Biotechnology ETF (IBB) rose 1.3%.In corporate news, Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico. Amgen shares were down 2.1%.Vanda Pharmaceuticals (VNDA) shares jumped past 5% after it said Monday its motion sickness drug Nereus is now commercially available in the US.Eli Lilly (LLY) shares added 0.2% after Barclays lifted the company's price target to $1,400 from $1,350, while keeping its overweight rating.Moderna (MRNA) is showing continued advancement across its pipeline, with progress in cancer vaccines and infectious disease programs supporting a more balanced risk-reward profile, RBC Capital Markets said in a note. RBC maintained its sector perform rating on the stock and raised its price target to $38 from $35. Moderna shares rose 4.6%.

$AMGN$LLY$MRNA$VNDA
Wire

Eli Lilly Keeps Quarterly Dividend at $1.73 a Share, Payable June 10 to Shareholders of Record as of May 15

Eli Lilly Keeps Quarterly Dividend at $1.73 a Share, Payable June 10 to Shareholders of Record as of May 15

$LLY
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Friday afternoon with the NYSE Health Care Index easing 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) falling 0.4%.The iShares Biotechnology ETF (IBB) shed 0.6%.In corporate news, Moderna (MRNA) affirmed its 2026 revenue growth outlook and reported better-than-expected Q1 results amid higher COVID vaccine sales. The stock still declined 1.4%.Amgen's (AMGN) Q1 EPS beat was primarily driven by lower administrative costs and taxes, Morgan Stanley said. Amgen shares fell 4.9%.Eli Lilly's (LLY) international rollout of its new oral weight-loss drug is off to a strong start, with early demand for Foundayo building quickly, BofA Securities said. Lilly shares rose 3.1%.Novo Nordisk (NVO) rebranded its oral semaglutide medication for type 2 diabetes as Ozempic. It was formerly marketed as Rybelsus. Novo shares gained 3.9%.

$AMGN$LLY$MRNA$NVO
Sectors

Sector Update: Health Care

Health care stocks were softer late Friday afternoon with the NYSE Health Care Index fractionally lower and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.4%.The iShares Biotechnology ETF (IBB) shed 0.7%.In corporate news, Eli Lilly's (LLY) international rollout of its new oral weight-loss drug is off to a strong start, with early demand for Foundayo building quickly, BofA Securities said in a report. Lilly shares were up 3%.

$LLY
Wire

Eli Lilly Strong Q1 Results Show Stable Pricing, Foundayo Volatility Remains, RBC Says

Eli Lilly (LLY) reported strong Q1 results driven by GLP-1 drugs, with fundamentals remaining solid and pricing stabilizing, RBC Capital Markets said, while warning that volatility around its new drug Foundayo remains.The company raised its full-year 2026 adjusted EPS outlook to $35.50 to $37 per share from $33.50 to $35 and reported Q1 results above expectations. RBC also lifted its full-year 2026 EPS forecast to $36.24 from $33.59 and increased its revenue estimate to $85.1 billion from $83.2 billion.Foundayo has reached about 20,000 prescriptions so far. The investment firm said it is still too early to assess demand and expects data to remain volatile as the launch develops.The brokerage said it was "encouraging" that Mounjaro prescriptions in India rose about 10% even after the entry of cheaper generics. It also noted that pricing trends have stabilized, with management reaffirming low-to-mid teens year-on-year declines.RBC maintained its outperform rating and $1,250 price target, saying the stock remains undervalued given long-term growth prospects.Price: $962.47, Change: $+27.87, Percent Change: +2.98%

$LLY
Wire

Eli Lilly's Oral Weight-Loss Drug Gains Early Momentum as Prescriptions Surge, BofA Says

Eli Lilly's (LLY) international rollout of its new oral weight-loss drug is off to a strong start, with early demand for Foundayo building quickly, BofA Securities said Thursday in a report.More than 20,000 patients were treated with Foundayo in the first 3.5 weeks, up from 5,000 in the first two weeks, BofA said. Lilly expects access through several major pharmacy benefit managers by mid-May and pointed to Zepbound's 55% share of new-to-brand prescriptions as the closest comparison for how early Foundayo uptake is trending, the report said.International demand for Mounjaro also remains strong, with about 75% of volume tied to chronic weight management rather than type 2 diabetes, the report said.BofA raised its 2026 sales forecast by 8% to $32.5 billion, reflecting continued strength across Lilly's incretin portfolio, and lifted its EPS estimate by 6% to $36.46, in line with updated company guidance.BofA cut its price target on Lilly stock to $1,133 from $1,294 after applying a lower valuation multiple to reflect longer-term pricing uncertainty. Its buy rating was reiterated.Price: $964.51, Change: $+29.91, Percent Change: +3.20%

$LLY
Research

Research Alert: CFRA Keeps Buy Rating On Shares Of Eli Lilly After Very Robust Start To 2026

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $1,225, 29.0x our 2027 EPS view, below LLY's five-year historical forward P/E average. We lift our 2026 EPS view to $36.97 from $34.71 and keep 2027's EPS at $42.22. LLY shares are up over 10% today after announcing a robust start to 2026, with Q1 revenue soaring 56% Y/Y to $19.8B, significantly beating our estimates and Street expectations. The strong performance was fueled by its incretin medicines, Mounjaro and Zepbound, which generated $12.8B combined. A key highlight of the Q1 earnings call was the FDA approval of Foundayo, the oral GLP-1 for weight management. We remain optimistic about Foundayo's potential to expand the obesity treatment market in the U.S. and overseas, given its convenience as a once-daily pill with no food or water restrictions. LLY is also demonstrating significant pipeline progress, including positive data for key assets such as Retatrutide, Jaypirca, and Ebglyss, plus four strategic acquisitions (Orna, Centessa, Kelonia, Ajax) to bolster its capabilities.

$LLY
Wire

BofA Securities Cuts Eli Lilly Price Target to $1,133 From $1,294, Maintains Buy Rating

Eli Lilly (LLY) has an average rating of overweight and mean price target of $1,241.57, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $974.57, Change: $+39.97, Percent Change: +4.28%

$LLY
Wire

Morgan Stanley Adjusts Eli Lilly Price Target to $1,344 From $1,327, Maintains Overweight Rating

Eli Lilly (LLY) has an average rating of overweight and mean price target of $1,241.57, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $979.68, Change: $+45.13, Percent Change: +4.83%

$LLY
US Markets

S&P 500, Nasdaq Notch New Peaks, Log Best Month Since 2020

The S&P 500 and the Nasdaq Composite hit new closing highs on Thursday, with the two equity indexes recording their biggest monthly gains since 2020.The S&P 500 rose 1% to 7,209, while the Nasdaq climbed 0.9% to 24,892.3, both logging record closing highs. The Dow Jones Industrial Average jumped 1.6% to 49,652.1. Barring technology, all sectors were in the green, led by communication services' 4% jump.This month, the Nasdaq jumped 15.3%, logging its best monthly performance since April 2020. The S&P 500 gained 10.4%, the biggest monthly gain since November 2020. The Dow climbed 7.1%.In company news, Alphabet's (GOOG, GOOGL) first-quarter results exceeded Wall Street's estimates late Wednesday as revenue for Google's cloud and services businesses climbed. Alphabet increased its 2026 capital expenditure guidance to up to $190 billion. Shares climbed 10%.Caterpillar (CAT) surged 9.9%, the best performer on the Dow. The heavy equipment manufacturer raised its full-year sales outlook as its first-quarter results exceeded market expectations.Eli Lilly (LLY) lifted its full-year outlook, while the drugmaker reported first-quarter results above market estimates. The stock advanced 9.8%.Meta Platforms (META) shares plunged 8.6%, among the steepest declines on the S&P 500. The Facebook parent late Wednesday raised its full-year capital expenditure guidance mainly due to higher component pricing.Microsoft (MSFT) shares declined 3.9%, the second-worst performer on the Dow, as the tech giant said late Wednesday its capital expenditure will be about $190 billion in 2026. The company's aggressive capital expenditure will likely keep free cash flow under pressure in the near term, Truist Securities said in a note.Brent crude fell 3.3% at $114.09 per barrel, having topped $126 earlier in the day. West Texas Intermediate fell 1.8% to $105.01.On Wednesday, the Federal Reserve kept its benchmark lending rate steady, saying the Iran war is fueling uncertainty around the US economic outlook.The most recent policy statement had an implied easing bias, but that could soon be removed amid a growing divide among policymakers over the direction of interest rates, Stifel said in a note Thursday.US Treasury yields were lower, with the 10-year rate down 2.4 basis points at 4.41% and the two-year rate falling 7.8 basis points to 3.89%.US economic growth fell short of Wall Street's expectations in the first quarter as spending slowed amid inflationary pressures that economists said will likely keep consumers under pressure."The core of the economy remained solid in (the first quarter), driven by the (artificial intelligence) buildout and the tax cuts beginning to feed through," Oxford Economics Chief US Economist Michael Pearce said in remarks emailed to. "Those factors will continue to drive growth over the rest of the year, but the jump in energy prices will take some of the shine off what would otherwise have been a strong year for the economy."Separate official data showed that US inflation, as measured by the personal consumption expenditure price index, accelerated in March to the fastest pace since mid-2022 as the Middle East conflict sent energy prices soaring."Inflationary pressures continued to percolate," Ksenia Bushmeneva, economist at TD Economics, said in a report. "The situation around the energy crisis remains uncertain and gas prices are likely to remain elevated for some time."Gold rose 1.6% at $4,635 per troy ounce, while silver advanced 2.9% to $74.18 per ounce.

Dow JonesNasdaq CompositeS&P 500$CAT$GOOG$GOOGL$LLY$META$MSFT
Sectors

Sector Update: Health Care Stocks Gain Late Afternoon

Health care stocks rose late Thursday afternoon with the NYSE Health Care Index climbing 2.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.The iShares Biotechnology ETF (IBB) advanced 1.9%.In corporate news, UniQure (QURE) shares jumped past 16% after the company said it plans to submit a UK marketing authorization application in Q3 for AMT-130 to treat Huntington's disease.Axsome Therapeutics (AXSM) shares surged 12% after it said the US Food and Drug Administration approved Auvelity to treat agitation associated with Alzheimer's disease dementia.Eli Lilly (LLY) raised its full-year outlook and reported Q1 results above market estimates as sales of Mounjaro more than doubled. Lilly shares jumped past 10%.The US Food and Drug Administration is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances. Eli Lilly makes tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) makes semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Novo shares rose past 5%.

$AXSM$LLY$NVO$QURE
US Markets

Equities Rise Intraday as Traders Track Earnings Reports; Oil Prices Pull Back

US benchmark equity indexes were higher intraday as investors digested the latest batch of corporate results, while oil prices turned lower.The Dow Jones Industrial Average was up 1.5% at 49,601.7 after midday Thursday, while the S&P 500 rose 0.7% to 7,187.1. The Nasdaq Composite climbed 0.5% to 24,800.9. Barring technology, all sectors were in the green, led by communication services' 3.5% jump.In company news, Caterpillar (CAT) shares surged 10% intraday, the best performer on the Dow and among the biggest gainers on the S&P 500. The heavy equipment manufacturer raised its full-year sales outlook as its first-quarter results exceeded market expectations.Eli Lilly (LLY) lifted its full-year outlook, while the drugmaker reported first-quarter results above market estimates. The stock was up 10%.Meta Platforms (META) shares plunged 9.2%, among the steepest declines on the S&P 500, as the Facebook parent raised its full-year capital expenditure guidance mainly due to higher component pricing.Microsoft (MSFT) shares were down 5.8%, the worst performer on the Dow, as the tech giant said its capital expenditures will be about $190 billion in 2026, while its fiscal third-quarter results topped market estimates.iPhone maker Apple (AAPL) is scheduled to release its quarterly earnings after the markets close.Oil prices pulled back after surging in the previous session, with Brent crude down 3.5% at $113.94 per barrel, having topped $126 earlier in the day. West Texas Intermediate fell 2.5% to $104.22.In economic news, US economic growth fell short of Wall Street's expectations in the first quarter as spending slowed amid inflationary pressures that economists said will likely keep consumers under pressure."The core of the economy remained solid in (the first quarter), driven by the (artificial intelligence) buildout and the tax cuts beginning to feed through," Oxford Economics Chief US Economist Michael Pearce said in remarks emailed to. "Those factors will continue to drive growth over the rest of the year, but the jump in energy prices will take some of the shine off what would otherwise have been a strong year for the economy."US inflation, as measured by the personal consumption expenditure price index, accelerated in March to the fastest pace since mid-2022 as the Middle East conflict sent energy prices soaring."Inflationary pressures continued to percolate," Ksenia Bushmeneva, economist at TD Economics, said in a report. "The situation around the energy crisis remains uncertain and gas prices are likely to remain elevated for some time."On Wednesday, the Fed kept its benchmark lending rate steady, saying the Iran war is fueling uncertainty around the US economic outlook.US Treasury yields were lower intraday, with the 10-year rate down 3.8 basis points at 4.40% and the two-year rate falling 6.9 basis points to 3.90%.Gold rose 1.3% at $4,620 per troy ounce, while silver advanced 2% to $73.51 per ounce.

Dow JonesNasdaq CompositeS&P 500$AAPL$CAT$LLY$META$MSFT
Sectors

Sector Update: Health Care Stocks Gain Thursday Afternoon

Health care stocks rose Thursday afternoon with the NYSE Health Care Index climbing 2.5% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.The iShares Biotechnology ETF (IBB) advanced 2%.In corporate news, Eli Lilly (LLY) raised its full-year outlook and reported Q1 results above market estimates as sales of Mounjaro more than doubled. Lilly shares jumped 10%.The US Food and Drug Administration is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances. Eli Lilly makes tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) makes semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Novo shares rose 5.0%.NovoCure (NVCR) shares surged 28% after the company posted Q1 results.

$LLY$NVCR$NVO
Sectors

Sector Update: Health Care

Health care stocks rose Thursday afternoon, with the NYSE Health Care Index climbing 2.4% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.3%.The iShares Biotechnology ETF (IBB) gained 2%.In corporate news, Eli Lilly (LLY) raised its full-year outlook and reported Q1 results above market estimates, as sales of Mounjaro more than doubled year over year. Lilly shares rose past 9%.

$LLY
Wire

Update: FDA Seeks to Exclude Tirzepatide, Semaglutide, Liraglutide From 503B Bulks List

(Updates with Lilly's comment in the third paragraph.)The US Food and Drug Administration said Thursday it is proposing to exclude tirzepatide, semaglutide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances.Eli Lilly (LLY) manufactures tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Novo Nordisk (NVO) manufactures semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management.In an emailed statement to, Lilly said it is "pleased FDA has confirmed there is no clinical need for compounded tirzepatide. That means there is no basis for compounders to make tirzepatide knockoffs. Lilly will continue working to protect patients from the risks associated with unapproved drugs prescribed without a medical need."Under federal law, outsourcing facilities generally cannot compound drugs from bulk substances unless the ingredient appears on the 503B bulks list or the compounded drug is on the FDA's drug-shortage list at the time of compounding, distribution and dispensing, the agency said.The FDA is accepting public comments on the proposal through June 29.Novo Nordisk didn't immediately reply to a request for comment from.Lilly shares jumped 9.8% in Thursday trading, and Novo Nordisk gained 5.7%Price: $934.57, Change: $+83.36, Percent Change: +9.79%

$LLY$NVO
Wire

Top Midday Stories: Tech Giants' Earnings Top Estimates, Reactions Mixed; Eli Lilly Lifts Outlook After Estimate-Beating Q1 Earnings

All three major US stock indexes were up in late-morning trading Thursday, as investors digest a slew of earnings reports from the giant tech companies as well as the Federal Reserve's decision Wednesday to leave interest rates unchanged.In company news, Meta Platforms (META) reported Q1 earnings late Wednesday of $10.44 per diluted share, up from $6.43 a year earlier and above the FactSet consensus analyst estimate of $6.67. Meta Q1 revenue was $56.31 billion, up from $42.31 billion a year ago and above the FactSet consensus of $55.56 billion. For Q2, Meta said it expects revenue of $58 billion to $61 billion, compared to the FactSet consensus of $59.48 billion. Full-year 2026 capital expenditures are expected to be between $125 billion and $145 billion, up from the prior outlook of $115 billion to $135 billion, Chief Financial Officer Susan Li said on a call with analysts. The daily active people average for March was 3.56 billion, up 4% year over year but down slightly quarter over year due to internet disruptions in Iran and WhatsApp restrictions in Russia, the company said. After the earnings report, Meta commenced a US investment-grade bond sale in as many as six parts through which it is looking to raise up to $25 billion. Meta shares were down 9.5% around midday.Alphabet (GOOG, GOOGL) reported Q1 earnings late Wednesday of $5.11 per diluted share, up from $2.81 a year earlier and above the FactSet consensus estimate of $2.63. Alphabet Q1 revenue was $109.9 billion, up from $90.2 billion a year ago and above the FactSet consensus of $106.96 billion. The tech giant raised it quarterly cash dividend to $0.22 per share from $0.21 per share, payable June 15 to shareholders of record as of June 8. Alphabet's Class C and Class A shares were up 7.2% and 7.3%, respectively.Amazon (AMZN) reported Q1 earnings late Wednesday of $2.78 per diluted share, up from $1.59 a year earlier and above the FactSet consensus of $1.63. Amazon Q1 revenue was $181.52 billion, up from $155.67 billion a year ago and above the FactSet consensus of $177.28 billion. For Q2, the company said it expects revenue of $194 billion to $199 billion, above the FactSet consensus of $188.96 billion. Amazon shares were down 1.2%.Microsoft (MSFT) reported fiscal Q3 adjusted earnings late Wednesday of $4.27 per diluted share, up from $3.54 a year earlier and above the FactSet consensus of $4.05. Fiscal Q3 revenue was $82.89 billion, up from $70.07 billion a year ago and above the FactSet consensus of $81.40 billion. Microsoft shares were down 4.5%.Eli Lilly (LLY) reported Q1 non-GAAP earnings Thursday of $8.55 per diluted share, up from $3.34 a year earlier and above the FactSet consensus of $6.97. Lilly Q1 revenue was $19.80 billion, up from $12.73 billion a year ago and above the FactSet consensus of $17.82 billion. For full-year 2026, the company said it expects adjusted EPS of $35.50 to $37.00, up from its previous guidance of $33.50 to $35.00 and above the FactSet consensus of $34.51. Full-year revenue is expected to be between $82 billion and $85 billion, up from its previous outlook of $80 billion to $83 billion and compared to the FactSet consensus of $82.07 billion. Eli Lilly shares were up 8.1%.Qualcomm (QCOM) reported fiscal Q2 adjusted earnings late Wednesday of $2.65 per diluted share, down from $2.85 a year earlier but above the FactSet consensus of $2.56. Fiscal Q2 revenue was $10.60 billion, down from $10.97 billion a year ago but above the FactSet consensus of $10.69 billion. For fiscal Q3, the company said it expects adjusted EPS of $2.10 to $2.30, below the FactSet consensus of $2.42. Fiscal Q3 revenue is expected to be between $9.20 billion to $10 billion, below the FactSet consensus of $10.19 billion. CFO Akash Palkhiwala said on the company's earnings call that the company expects shipments to Chinese Android customers to recover after inventory corrections. Qualcomm also said it has secured a "multi-generation engagement" with a leading hyperscaler, with initial shipments expected to begin later this year. Qualcomm shares were up 18.0%.Caterpillar (CAT) reported Q1 adjusted profit Thursday of $5.54 per share, up from $4.25 a year earlier and above the FactSet consensus of $4.65. Total Q1 sales and revenue were $17.42 billion, up from $14.25 billion a year ago and above the FactSet consensus of $16.53 billion. For full-year 2026, the company said it expects low double-digit sales and revenue growth, higher year-over-year free cash flow in its primary operating segment of machinery, power and energy, and adjusted operating profit margin near the bottom of the target range. Caterpillar shares were up 8.6%.Mastercard (MA) reported Q1 adjusted earnings Thursday of $4.60 per diluted share, up from $3.73 a year earlier and above the FactSet consensus of $4.41. Net Q1 revenue was $8.40 billion, up from $7.25 billion a year ago and above the FactSet consensus of $8.26 billion. Mastercard shares were down 3.6%.Stellantis (STLA) reported Q1 adjusted earnings Thursday of 40.21 per diluted share, upf rom $0.04 a year earlier and above the FactSet consensus of $0.19. Net Q1 revenue was $38.13 billion, up from $25.81 billion ay ear ago but below the FactSet consensus from four analysts of $44.95 billion. For full-year 2026, the company said it expects mid-single-digit net revenue growth. Stellantis shares were down 4.9%.Price: $606.15, Change: $-62.97, Percent Change: -9.41%

$AMZN$CAT$GOOG$GOOGL$LLY$MA$META$QCOM$STLA
Wire

FDA Proposes to Exclude Semaglutide, Tirzepatide, Liraglutide From 503B Bulks List

The US Food and Drug Administration said Thursday it is proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound the drugs from bulk substances.Novo Nordisk (NVO) manufactures semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management, and liraglutide, under the brand name Victoza for type 2 diabetes and Saxenda for chronic weight management. Eli Lilly (LLY) manufactures tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.Normally, outsourcing facilities cannot compound drugs using bulk drug substances unless the substance is on the 503B bulks list or the compounded drug is on the FDA's drug shortage list at the time of compounding, distribution, and dispensing, the FDA said.Novo Nordisk and Eli Lilly didn't immediately reply to requests for comment from.Price: $42.48, Change: $+2.19, Percent Change: +5.44%

$LLY$NVO

Showing 101-120 of 147

Track with the FINWIRES app suite

FolioX
FolioX
Track Eli Lilly and Company in your portfolio
WheelAI
WheelAI
Analyze Eli Lilly and Company options with the wheel strategy
StockInsider
StockInsider
See market sentiment on Eli Lilly and Company